PharmaShots’ Most Read News of 2022

The year 2022 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements, clinical trial results and gaining approvals. Our team has compiled a list of 30 most read life sciences news on PharmaShots in 2022 1. AVEO Entered into a Clinical Trial Collaboration with Merck KGaA to…

BySenior EditorJanuary 2, 2023

INSIGHTS+

PharmaShots’ Key Highlights of Fourth Quarter 2022

Shots: The fourth quarter of 2022 highlights approvals, multiple clinical trial results, and numerous deals. There are major alliances in this quarter which include Johnson & Johnson acquired Abiomed for ~$16.6B, Takeda entered into an agreement to acquire NDI-034858 from Nimbus Therapeutics for ~$6B In the fourth quarter of the year, BeiGene’s Brukinsa received EC’s…

BySenior EditorDecember 29, 2022

INSIGHTS+

Insights+ Key Biosimilars Events of November 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of November, Samsung Bioepis presented two P-III studies results…

BySenior EditorDecember 1, 2022

INSIGHTS+

Insights+: The US FDA New Drug Approvals in September 2022

The US FDA approved 12 NDAs and 4 BLA in September 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 63 novel products in 2022 In September 2022, the major highlights drugs were Spevigo’s approval for generalized pustular psoriasis flares, Imfinzi for advanced biliary tract cancer, Retevmo…

BySenior EditorOctober 20, 2022

TOP 20

Top 20 Oncology Companies Based on 2021 Oncology Segment Total Revenue

Shots: Oncology focuses on the study, diagnosis, prevention, and treatment of cancer based on the treatment option and it’s divided into 3 major areas including medical oncology, radiation oncology, and surgical oncology The advancements in cell and gene therapies have provided pharmaceutical companies with a unique set of ground-breaking tools for the development of more…

ByPrince GiriSeptember 8, 2022

VIEWPOINTS

Leonard Glass, Vice President, Global Medical Affairs at Eli Lilly & Co. Shares Insights from Lilly’s Vision on New Stage of Metabolic Science

Shots: Leonard spoke about how Lilly is advancing in the field of metabolic disease research (esp. diabetes) He also talked about its lead candidate in type 2 diabetes and also discussed its clinical results in detail The interview summarizes Lilly’s objective to advance new discoveries and redefine diabetes care Smriti: Tell us how Lilly is leading…

BySenior EditorAugust 16, 2022

TOP 20

Top 20 Immunology Companies Based on 2021 Immunology Segment Total Revenue

Shots: Immunology focuses on analyzing all aspects of the immune system in both healthy and diseased states, from its structure & function to its disorders, blood banking, immunization & organ transplant Along with the enhanced utilization of immunotherapies for immunological & autoimmune diseases, monoclonal antibodies have also showcased a great potential to be used as…

ByPrince GiriAugust 11, 2022

INSIGHTS+

Insights+: The US FDA New Drug Approvals in June 2022

The US FDA approved 2 NDAs and 2 BLA in June 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 37 novel products in 2022 In June 2022, the major highlights drugs were Amvuttra's approval for polyneuropathy of hereditary transthyretin-mediated amyloidosis, Skyrizi for active Crohn's disease, Olumiant…

BySenior EditorJuly 21, 2022

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2022

The second quarter of 2022 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, AstraZeneca’s Farxiga (dapagliflozin) meet its primary endpoints for heart failure with a preserved ejection fraction Starting with the latest acquisitions, Pfizer acquire Biohaven for ~$11.6B, GSK acquire Affinivax for ~$3.3B. The second quarter of the year…

BySenior EditorJune 30, 2022

TOP 20

Top 20 BioPharma Companies based on 2021 Total Revenue

While the COVID-19 pandemic has dominated the healthcare space for the last two years, some biopharma companies were involved in multiple deals, M&A, and the development of various drug candidates in other areas to diversify their portfolios While top Biopharma companies remain on the chart, however, in 2021, new players like Moderna, BioNTech, Viatris also…

ByPrince GiriApril 14, 2022

PharmaShots’ Most Read News of 2022

PharmaShots’ Key Highlights of Fourth Quarter 2022

Insights+ Key Biosimilars Events of November 2022

Insights+: The US FDA New Drug Approvals in September 2022

Top 20 Oncology Companies Based on 2021 Oncology Segment Total Revenue

Leonard Glass, Vice President, Global Medical Affairs at Eli Lilly & Co. Shares Insights from Lilly’s Vision on New Stage of Metabolic Science

Top 20 Immunology Companies Based on 2021 Immunology Segment Total Revenue

Insights+: The US FDA New Drug Approvals in June 2022

PharmaShots’ Key Highlights of Second Quarter 2022

Top 20 BioPharma Companies based on 2021 Total Revenue

Contact US

FOLLOW US